Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison
Authors' conclusion
In these aITCs, glycated haemoglobin and weight reductions were significantly greater for all tirzepatide doses versus semaglutide 0.5 mg with a comparable AE profile. These findings provide comparative effectiveness insights in the absence of a head-to-head clinical trial.
Study context
- Population
- Adults with T2D, second-line treatment after metformin monotherapy
- Comparison
- Tirzepatide 5, 10 and 15 mg vs subcutaneous semaglutide 0.5 mg
- Outcome
- HbA1c, body weight and BMI reduction
- Follow-up
- Baseline to week 40
Methodological detailsBucher method, common comparator (subcutaneous semaglutide 1.0 mg), based on SURPASS-2 and SUSTAIN7
- Bucher method
- Common comparator (subcutaneous semaglutide 1.0 mg)
- Based on SURPASS-2 and SUSTAIN7
Main finding
As reported in the abstract
- All tirzepatide doses: significantly greater reductions in HbA1c, body weight and BMI vs semaglutide 0.5 mg
Further findings
HbA1c targets ≤ 6.5 % (≤48 mmol/mol) and < 7.0 % (<53 mmol/mol); weight loss targets ≥ 5 % and ≥ 10 %
- All tirzepatide doses: greater odds of achieving HbA1c and weight loss targets vs semaglutide 0.5 mg
Safety
- Comparable adverse event (AE) profile; no significant differences in odds of gastrointestinal AEs vs semaglutide 0.5 mg
Original publication
Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison. Diabetes Res Clin Pract. Published 21 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →